You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Monica Heger tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb.
The national project has developed infrastructure for implementing genomics into clinical care and is now studying clinical utility and cost effectiveness.
The company, which spun out of the Netherlands Cancer Institute, has developed technology to identify promoters and enhancers.
The UCSF spinout aims to develop noninvasive tests to detect kidney injury for the transplantation field and to diagnose and monitor chronic disease.
A Personalized Medicine Coalition-funded study has found that NGS-based testing is moderately cost effective but that access to targeted treatments remains a hurdle.
During an NIH meeting, researchers from four newborn sequencing research projects discussed results of their studies and future implications.
With funding from the Bill and Melinda Gates Foundation, the Biohub will help implement metagenomic sequencing for infectious disease projects in 10 countries.
Stakeholders discussed last year's decision by Palmetto to deny coverage for large respiratory panels and discussed the way forward for test developers and labs.
The researchers found that dark regions impact more than 700 protein-coding genes and also identified a novel mutation in a known Alzheimer's disease gene.
The team is now conducting additional studies of mNGS in plasma, as well as looking to reduce turnaround time by running the test on a nanopore sequencer.
In a pilot study, EMD Serono will have the genomes of lung cancer patients sequenced for research but participants will also gain access to their genomic data.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.